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A major obstacle to control and cure HIV is the persistence of latent viral reservoirs within the bodies 
of infected people. Highly active antiretroviral therapy (HAART) reduces the spread of HIV by 
inhibiting viral replication, but does not eliminate these viral reservoirs. Unfortunately, some HIV-
infected individuals cannot tolerate long-term HAART due to severe side effects, or develop 
multidrug resistant virus. In one remarkable instance, an HIV-positive patient was "cured" of infection 
while being treated for acute myeloid leukemia. This patient received a stem cell transplant from a 
donor who had a rare genetic mutation that makes cells resistant to HIV infection. The mutation in 
the gene CCR5 prevented the expression of the CCR5 co-receptor necessary for HIV binding and 
entry into cells. Unfortunately, this approach is limited in its applicability since finding a matched 
donor for transplant is extremely rare and allogeneic stem cell transplantation has significant 
associated morbidities. However, the elimination of HIV in one patient suggests that genetically 
engineering a patient’s own immune cells to be HIV-resistant could prove to be a viable therapeutic 
strategy. Lead author Dr. Patrick Younan and colleagues in the laboratory of Dr. Hans-Peter Kiem 
(Clinical Research Division) demonstrate for the first time the possible benefits of this strategy to 
treat HIV-positive patients in a clinically relevant nonhuman primate AIDS model. 
Clinical trials are under way using zinc finger nucleases that specifically target and inactivate the 
CCR5 gene in peripheral T-cells of HIV-infected patients. However, other HIV strains use a different 
co-receptor, CXCR4, and would not be inhibited by this strategy. An alternative strategy for making 
cells resistant to HIV infection is genetically-engineering cells to express a fusion inhibitor, mC46. By 
binding the viral protein gp41, mC46 disrupts the HIV molecular machinery needed for the fusion of 
the viral membrane to the host cell membrane. Initial clinical trials demonstrated that modifying a 
patient’s T-cells to express mC46 is well tolerated in HIV-positive patients (Van Lunzen K et al., 
2007). An improved strategy would be to express mC46 on hematopoietic stem cells (HSCs), which 
would provide protection to both lymphoid and myeloid cells susceptible to HIV infection and provide 
a source of long-lived modified progenitor cells. 
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Mouse models of HIV infection facilitate rapid functional testing of the gene-modified cells, but 
nonhuman primate models are necessary to determine the conditions necessary to achieve 
sufficient stem cell engraftment and long-term protection from HIV in humans. Younan et al. 
transplanted four pigtail macaques with genetically-modified HSCs with identical pre- and post-
transplant conditioning regimens. Two animals received control HSCs and two animals received 
mC46-expressing HSCs.  Both control and mC46-expressing HSC were engineered to express a 
chemotherapy-resistance gene and green-fluorescent protein (GFP) with a lentiviral vector to enrich 
for the modified cells in vitro by GFP and in vivo by chemotherapy treatment. This treatment allowed 
for sufficient numbers of modified cells to recover in the animal for two weeks before infection: one 
animal recovered with 20% modified CD4+ T-cells (mC46.1) and the other animal 55% (mC46.2). 
All animals were infected with a highly pathogenic chimera HIV/SHIV strain that uses both CCR5 
and CXCR4 as co-receptors. During the acute phase of the infection, there was an initial drop in 
mC46-modified T-cell numbers, most likely due to bystander mediated-apoptosis and not direct 
infection. Three weeks after infection, both mC46.1 and mC46.2 macaques increased mC46-
modified CD4+ T-cells to greater than 90% of the total T-cell numbers, while no selective advantage 
was observed in the control animals. At five months after infection the researchers also found 
recovery of CD4+ T-cells that were not modified to express mC36.1 close to normal levels in the 
monkeys that received mC46.1-modified HSCs, a result not found in mouse AIDS models. A more 
moderate increase in unmodified CD4+ T-cells was observed in mC46.2 that could be due to the 
higher percentage of modified T-cells recovered before infections. 
Strikingly, an enhanced immune response was observed in the mC46 transplanted macaques, with 
maintenance of SHIV-specific CD4+ T-cells and cytotoxic CD8+ T-cells, and antibody responses 
against the infected SHIV strain. Six months after SHIV-infection, serum samples showed 
neutralization of viral infection with more than four-fold activity in mC46 macaques versus controls. 
The researchers propose the preservation of SHIV antigen-specific CD4+ T cells can contribute to 
boosting the development of virus-specific memory CD8+ T-cells and neutralizing antibodies. 
Studies of human patients who are long-term non-progressors and elite controllers of HIV infection 
suggest that maintenance of HIV-specific CD4+ T-cells enhances the ability of the immune system to 
suppress viral replication.  As such, the mC46 macaques did not show disease progression to AIDS 
in the absence of antiretroviral treatment. Plasma viremia was 320-fold lower in the mC46.1 at day 
168, and 1,477-fold lower in mC46.2 at day 20 compared to their respective controls (p=0.02). 
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According to Drs. Kiem and Younan, "these results suggest that genetically modifying hematopoietic 
stem cells not only results in the protection of gene-modified immune cell populations, but also 
provides these infection-resistant cells the opportunity to elicit an enhanced immune response 
against the virus." Since this study introduced modified stem cells before viral infection, it will be 
necessary to examine the protective effect in animals infected with SHIV/HIV prior to transplant. 
Realistically, human treatment of this nature would be initiated after initial infection. Notably, mC46 is 
structurally similar to the FDA-approved fusion inhibitor enfuvirtide. HIV can mutate and become 
resistant to the effects of enfuvirtide in the absence of additional antiretroviral therapies in humans; 
therefore, it is possible that mC46-modified immune cells may also elicit HIV strains resistant to 
mC46 binding. Nevertheless, Drs. Kiem and Younan provocatively ask, "Is it possible that by 
rendering immune cells resistant to infection and enhancing the immune response to HIV that we 
may be able to develop strategies to also eradicate HIV?" 
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Genetic modification of immune cells to express the fusion 
inhibitor mC46 blocks infection of all HIV strains with tropism for 
CCR5 (R5), CXCR4 (X4) or both co-receptors (X4/R5). Sparing 
a subset of CD4+ T-cells from infection boosts the immune 
response against HIV through various mechanisms, including 
enhanced cytotoxic T-cell and antibody responses. 
 
